Study of Cabozantinib (XL184) Versus Mitoxantrone plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)

Objectives: This phase III trial asks whether third-line cabozantinib, a novel oral multi-targeted tyrosine kinase inhibitor, can improve pain and bone scan responses compared with mitoxantrone (Novantrone) plus prednisone.

Key entry or exclusion criteria: Patients must have received prior docetaxel (Taxotere) plus either abiraterone (Zytiga) or MDV3100 (enzalutamide) treatment, and bone metastases that require opioid narcotic intervention for pain.

Locations: 20 sites.

Goal: 246 patients.

Study sponsor: Exelixis

Link for more information: clinicaltrials.gov/ct2/show/NCT01522443

NIH clinical trials identifier: NCT01522443